AVEO News Alert Aveo Pharmaceuticals (AVEO) 0.82 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aveo Pharmaceuticals (AVEO) 0.82 $AVEO

Aveo up on (old) news of Klarman stake
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 11:00AM CST

OPHT: 44.93 (+1.06), AVEO: 0.82 (+0.01)

The New Baupost Biotech Picks
Matthew Finston - at Seeking Alpha - Mon Dec 15, 8:53AM CST

BIIB: 340.89 (+5.13), FWP: 20.13 (-0.17), MRK: 57.46 (+0.25), AVEO: 0.82 (+0.01), IDIX: 24.50 (+0.05), ATRA: 28.00 (+0.41), THRX: 14.55 (+0.22), TBPH: 14.84 (+0.20), PRTK: 37.70 (+1.30), KIN: 6.77 (+0.11), KERX: 14.00 (+0.20)

Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST

OCN: 14.88 (-0.14), KOS: 8.31 (-0.06), KIN: 6.77 (+0.11), VSAT: 63.75 (-0.20), RFMD: 16.59 (+0.29), EBAY: 57.10 (-0.12), TQNT: 27.72 (+0.50), IDIX: 24.50 (+0.05), SEMI: 18.72 (-0.39), VRTV: 50.15 (+0.09), THRX: 14.55 (+0.22), TBPH: 14.84 (+0.20), IMOS: 23.04 (+0.18), ELOS: 9.53 (-0.02), MU: 34.91 (-0.06), AR: 42.50 (-0.64), NCQ: 0.55 (unch), PBF: 25.99 (+0.15), LNG: 71.64 (-0.12), ATRA: 28.00 (+0.41), KERX: 14.00 (+0.20), NG: 2.82 (+0.10), AOI: 1.58 (unch), FWP: 20.13 (-0.17), BYD: 12.28 (+0.14), ALDW: 12.24 (-0.12), SUNE: 19.50 (+0.01), MRK: 57.46 (+0.25), AVEO: 0.82 (+0.01), AIG: 56.28 (-0.16)

AVEO Gains on Tivozanib Agreement with Ophthotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:20PM CST
AVEO Pharmaceuticals' (AVEO) shares gained around 10.9% ever since the company announced a deal with Ophthotech (OPHT).
OPHT: 44.93 (+1.06), AVEO: 0.82 (+0.01), AMAG: 43.02 (+0.90)

Aveo licenses tivozanib to Ophthotech
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:55AM CST

OPHT: 44.93 (+1.06), AVEO: 0.82 (+0.01)

AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF inhibitor) for the Treatment of Ocular Diseases
Business Wire - Tue Nov 11, 5:42AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO's small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.
AVEO: 0.82 (+0.01), OPHT: 44.93 (+1.06)

AVEO Pharmaceuticals misses by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:55PM CST

AVEO: 0.82 (+0.01)

Will AVEO Pharmaceuticals (AVEO) Surprise this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 4:10PM CST
AVEO Pharmaceuticals (AVEO), which is expected to report third-quarter 2014 results on Nov 6, had delivered a positive earnings surprise of 7.89% last quarter.
BIIB: 340.89 (+5.13), AVEO: 0.82 (+0.01), INFI: 16.65 (+0.37), HSP: 62.60 (-0.07)

AVEO Oncology Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 3:17PM CST
AVEO Oncology (NASDAQ:AVEO) today reported its third quarter 2014 financial results and provided an overview of its progress toward achieving its strategic plan.
AVEO: 0.82 (+0.01)

Global Cancer Kinase Inhibitors Market & Pipeline Insight 2014: 649 Pipeline Drugs & 35 Marketed Drugs
M2 - Mon Oct 13, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btwzfw/global_cancer) has announced the addition of the "Global Cancer Kinase Inhibitors Market & Pipeline Insight" report to their offering. The recent years have witnessed the emergence of kinase inhibitors, which have the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past two decades, the researchers have increased their learning about the functioning of these inhibitors, which has led to the achievement of significant milestones of development during this period. The use of inhibitors for treating cancer is gradually increasing. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's acceptance of inhibitors so as to develop more efficient drugs. The field of cancer is growing mainly because of the globally aging population, increasing rates of obesity and rising smoking rates across all regions. This opens the door of opportunities for the drug makers globally because the kinase inhibitors is highly competitive and is currently in growing stages, thus offering significant areas of unmet medical need. The future years are likely to witness significantly increased levels of activity in the development of these drugs. Additionally, with the industry undergoing the period of patent cliff, the pharma companies are rapidly working towards filling up their exhausting pipelines with alternative and innovative drugs. Kinase inhibitors fit these spaces most appropriately, which is likely to drive future growth and improve the survival rates of cancer patients. Global Cancer Kinase Inhibitors Market & Pipeline Insight Report Highlights: - Classification & Mechanism of Kinase Inhibitors - Cancer Kinase Inhibitors Therapy Market Overview - Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country - Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country - Patent Analysis & Orphan Designation of Kinase Inhibitors - Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs - Marketed Cancer Kinase Inhibitors: 35 Drugs Key Topics Covered: 1. Introduction to Kinase Inhibitors 2. Kinase Inhibitors Classification 3. Mechanisms of Kinase Inhibitors 4. Need for Cancer Kinase Inhibitor Therapy 5. Cancer Kinase Inhibitors Therapy Market Overview 6. Cancer Kinase Inhibitors Therapy Market Dynamics 7. Cancer Kinase Inhibitors Therapy Market Future Outlook 8. Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country 9. Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country 10. Suspended & Discontinued in Cancer Kinase Inhibitors Therapy Pipeline 11. Competitive Landscape - AVEO Pharmaceuticals - Amgen - AstraZeneca - Bayer HealthCare Pharmaceuticals - Boehringer Ingelheim - Deciphera Pharmaceuticals - Genentech - GlaxoSmithKline - Incyte Corporation - Novartis - Pfizer - Takeda For more information visit http://www.researchandmarkets.com/research/bt...bal_cancer
INCY: 71.57 (+1.99), AVEO: 0.82 (+0.01), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66)

HILL, AVEO, ORBC Expected To Be Down Before Next Earnings Releases
M2 - Tue Oct 07, 5:22AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and December earnings reports. Dot Hill Systems Corp (NASDAQ:HILL), Aveo Pharmaceuticals Inc (NASDAQ:AVEO), ORBCOMM Inc (NASDAQ:ORBC) are all expected to be Down Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down Before earnings are released Thursday:
HILL: 4.53 (+0.17), AVEO: 0.82 (+0.01), ORBC: 6.71 (+0.17)

AVEO-Biodesix Reveal Lung Cancer Study Exploratory Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 2:30PM CDT
AVEO Pharmaceuticals, Inc. (AVEO) and Biodesix announced data from an exploratory analysis of patients suffering from non small cell lung cancer (NSCLC) in a phase II study on ficlatuzumab.
MDVN: 99.23 (+1.23), GILD: 91.29 (+1.84), AZN: 70.44 (+0.26), AVEO: 0.82 (+0.01)

BioMed Leases Space to Baxter for R&D Center in MA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 9:40AM CDT
BioMed Realty Trust, Inc. (BMR) inked a new deal with Baxter Healthcare Corporation for leasing around 200,000 square feet of space in Cambridge, MA.
BMR: 21.76 (-0.15), PRU: 91.45 (-0.03), BAX: 74.45 (-0.04), AVEO: 0.82 (+0.01)

AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced Colorectal and Kidney Cancers Presented at ESMO 2014 Congress
Business Wire - Mon Sep 29, 5:45AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the European Society for Medical Oncology (ESMO), taking place September 25-30 in Madrid, Spain. Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) with a long half-life and activity against all three VEGF receptors.
AVEO: 0.82 (+0.01)

AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress
Business Wire - Mon Sep 29, 5:00AM CDT
AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective exploratory analysis using VeriStrat(R), a commercially available serum protein test, to identify patients most likely to benefit from the addition of ficlatuzumab, AVEO's HGF inhibitory antibody, to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy in a randomized Phase 2 study of ficlatuzumab and gefitinib (IRESSA(R)) in previously untreated Asian subjects with non-small cell lung cancer (NSCLC). The results, presented in a poster session (abstract #8195) at the 2014 Congress of the European Society for Medical Oncology (ESMO), suggest that VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.
AVEO: 0.82 (+0.01)

AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference
Business Wire - Fri Sep 26, 10:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company's potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in various in vivo cachexia models and in vitro assays at the 2nd Cancer Cachexia Conference, being held September 26-28, 2014, in Montreal, Canada. In addition to the poster presentations, the AVEO research was selected for presentation in an oral session titled "Targeting GDF15 with the inhibitory antibody AV-380 for the treatment of Cancer Cachexia."
AVEO: 0.82 (+0.01)

AVEO Oncology Announces Lease Termination and Amendment to Debt Financing Facility
Business Wire - Fri Sep 26, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that, as part of its plan to decrease operational expenses, the Company has entered into a termination of its lease agreement pertaining to the Company's headquarters in Cambridge, Massachusetts, reducing its existing lease obligations by $110 million. In addition, the Company has amended its debt financing facility with Hercules Technology Growth Capital (HTGC). Combined, these transactions do not impact the Company's prior financial guidance, with existing cash, cash equivalents and marketable securities providing resources to fund its operating plan into the fourth quarter of 2015 with an expected 2014 year-end cash balance of $50-55 million.
HTGC: 15.13 (+0.39), AVEO: 0.82 (+0.01)

Clinical Data on AVEO Oncology's Ficlatuzumab and Tivozanib to Be Presented at the ESMO 2014 Congress
Business Wire - Wed Sep 17, 5:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that clinical data on ficlatuzumab, the Company's hepatocyte growth factor (HGF) inhibitory antibody, as well as tivozanib, the Company's inhibitor of vascular endothelial growth factor (VEGF) 1, 2, and 3 receptors, will be presented at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, September 26 - September 30, 2014.
AVEO: 0.82 (+0.01)

AVEO Pharmaceuticals (AVEO) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 8:00AM CDT
AVEO Pharmaceuticals (AVEO) Shares March Higher, Can It Continue?
AVEO: 0.82 (+0.01)

Biotechnology Stocks to Keep an Eye On
ACCESSWIRE - Wed Aug 20, 8:01AM CDT
Deerfield Beach, FL / Aug 20, 2014 / It has been a disappointing year for biotechnology stocks so far after last year's surge. The correction was expected after last year's surge; however, the losses were accentuated after Fed Chair Janet Yellen's comments earlier this year regarding a possible bubble in biotech and social media stocks.
ACHN: 13.06 (+1.22), AVEO: 0.82 (+0.01), AEGR: 21.59 (-0.27), RTGN: 3.65 (+0.10)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 76

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 40

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 79

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 42

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading

Top 5 Most Recently Viewed Articles

Forian Inc.'s Key Participation in ROTH MKM Annual Event

Updated Category News Views 92

Forian Inc. Engages at ROTH MKM Technology Event In a significant move within the technology sector, Forian Inc. (Nasdaq: FORA) is preparing for participation in the prestigious ROTH MKM 13th Annual Technology Event. The event promises an engaging platform for discussions surrounding technological advancements and investment opportunities. Who Will Represent Forian Inc.?...

Continue Reading
Davidson Kempner Capital Management Updates Direct Line Holdings

Updated Category News Views 202

Introduction to the Disclosure This article provides an overview of a significant disclosure regarding holdings in Direct Line Insurance Group PLC by Davidson Kempner Capital Management LP. As a major financial actor, Davidson Kempner plays a critical role in the financial ecosystem, particularly in how it approaches its investments and holdings. Key Information on...

Continue Reading
Uncovering Dropbox's Unique Marketing Strategies for Success

Updated Category News Views 360

Drew Houston’s Key Marketing Insights Dropbox (NASDAQ: DBX) has transformed from a simple file storage service into a multibillion-dollar enterprise, largely due to the strategic marketing insights shared by CEO Drew Houston. During a notable event at Stanford University, he discussed two crucial hacks that have led to a surge of paying customers. The core idea is...

Continue Reading
22nd Century's Transformation: Debt Erased, Growth Ahead

Updated Category News Views 229

22nd Century Group Transforms with Debt-Free Balance Sheet 22nd Century Group, Inc. (NASDAQ: XXII) has made significant strides in its financial stability by completely eliminating $3.9 million in senior secured debt. This remarkable feat not only lowers their ongoing cash needs but resets the financial landscape for the company, enabling them to redirect resources...

Continue Reading
Empowering QUBT Shareholders: Your Rights and Legal Options

Updated Category News Views 170

Understanding Your Rights as a Shareholder of Quantum Computing Inc. As a shareholder of Quantum Computing Inc. (NASDAQ: QUBT), it's essential to be aware of your rights regarding the ongoing legal issue facing the company. You may have heard of a recent class action lawsuit aimed at Quantum Computing, and it's vital to understand how this could impact you as an investor....

Continue Reading